Biomea Fusion (BMEA) Launches Underwritten Public Offering; Shares Fall

Biomea Fusion, Inc. (BMEA) announced an underwritten public offering of common stock on September 23, 2026, alongside pre-funded warrants for certain investors. The clinical-stage diabetes and obesity company's shares fell following the disclosure. The offering includes common shares and pre-funded warrants to purchase common stock. Terms such as the number of shares and pricing were not disclosed in the initial announcement. Biomea Fusion focuses on developing therapies for diabetes and obesity. Further details on the capital raise are expected as the offering proceeds.